These are some factories producing vaccines that
need gifting, bit out of my reach for awhile. I did
the Chiron Liverpool plant some years ago and it
coincidently had a contamination problem soon
after losing
them about £12 million if I recall right. I have to
drive by GSK UK HQ on my way into London.
France. The vaccine production facility in
St Amand-Les-Eaux, which is located close to
Valenciennes, in the North of France,.....expected
to be operational in 2011 ( vaccine for the
prevention cervical cancer; and an “improved” flu
vaccine to protect against seasonal influenza. GSK’s
new meningitis vaccines will also be manufactured at
this site together with a paediatric vaccine
designed to protect against protection against
Streptococcus pneumonia and non-typeable Haemophilus
influenzae.) The new site will house a freeze drying
plant which will transform vaccines from a liquid
into a solid powder. This very complex operation is
used to enhance the shelf-life and stability of a
number of GSK’s innovative vaccines. The site will
also be equipped with a liquid plant for filling
syringes and vials, a packing plant and warehouse, a
power plant and quality control laboratories.
In Europe, in July 2005, GSK invested € 94.3 million
to double the production capacity for its
InflusplitTM/FluarixTM flu vaccine in Dresden,
Germany. In September 2005, GSK opened its Euros
150 million state-of-the-art-facility in Gödöllö,
Hungary, which is dedicated to the primary
production of diphtheria and tetanus bacterial
substances and whooping cough (pertussis) antigens
used in several paediatric combination vaccines.
In North America, in 2005, GSK made three important
acquisitions. It acquired a secondary manufacturing
site, based in Marietta, Pennsylvania, for
cell-culture-based flu vaccines. Seattle-based
Corixa Corporation, a developer of innovative
products (adjuvants) that stimulate immunity. In
December, GSK acquired ID Biomedical which provides
GSK with a significant increase in flu vaccine
manufacturing capacity to address both seasonal and
pandemic influenza threats.
In Asia, in June 2006, GSK announced its first
primary vaccine manufacturing plant in Singapore.
The new vaccine plant is GSK’s biggest vaccine
investment in Asia. The company will spend more than
S$300 million over the next four years on the first
phase of development of the plant dedicated to the
primary production of paediatric vaccines.
GSK Biologicals is headquartered in Rixensart,
Belgium, where the majority of GlaxoSmithKline’s
activities in the field of vaccine research,
development and production are conducted.
http://www.gsk.com/media/pressrelea...9_29_GSK906.htm
Merck: MERCK & CO. HELD ITS OFFICIAL groundbreaking
ceremony in October 2008 for its new
vaccine-manufacturing facility in Durham that
will create about 200 jobs and up to $300 million in
investment.
http://findarticles.com/p/articles/mi_m0UFV/is_6_18/ai_n6364593
AVANT Opens State-of-the-Art Vaccine Manufacturing
Facility in Fall River, MA
http://findarticles.com/p/articles/...v_5/ai_n6331575
In 2005, Sanofi Pasteur initiated a $150m investment
in the US at Swiftwater in Pennsylvania for a
new influenza vaccine manufacturing facility
http://www.pharmaceutical-technolog...pasteurvaccine/
BEGRIVAC vaccine is manufactured at Chiron's
facility in Marburg, Germany. Chiron's
facility in Siena/Rosia, Italy, produces
AGRIPPAL(R)
http://www.mindfully.org/Health/200...cine15jul05.htm